Canaccord Genuity lowers Cibus stock price target after equity raise

Published 05/06/2025, 18:04
Canaccord Genuity lowers Cibus stock price target after equity raise

On Thursday, Canaccord Genuity analysts adjusted their price target for Cibus stock (NASDAQ: CBUS) to $15 from $17.50. The move comes in response to a recent equity raise by the company. Currently trading at $1.57 with a market cap of $81.15 million, the stock has seen a significant decline of 29% in the past week. Despite the lowered price target, the analysts maintained their Buy rating on the stock. According to InvestingPro analysis, the company shows signs of rapid cash burn, with analyst targets ranging from $2 to $25.

The adjustment in the price target reflects the dilution impact due to the revised share count following the capital raise. Canaccord Genuity has also factored in an additional equity raise in its model over the forecast period.

The analysts used a discounted cash flow (DCF) model extending through 2032 to calculate the new price target. The model employs a weighted average cost of capital (WACC) of 20% and a perpetual growth rate of 2%.

The decision to maintain a Buy rating indicates continued confidence in Cibus’s long-term potential, despite the near-term adjustments to the price target.

In other recent news, Cibus Inc has reported a significant increase in revenue for the first quarter of 2025, reaching $1 million, up from $511,000 in the previous year. However, the company also faced a widening net loss of $49.4 million, primarily due to increased SG&A expenses. In an effort to raise capital, Cibus announced a public offering of approximately 15.7 million shares of Class A Common Stock at $1.75 per share, expected to gross around $27.5 million. The offering includes purchases by institutional investors and the company’s Chairman of the Board. Proceeds from this offering will be used to develop weed management productivity traits in rice and for general corporate purposes. A.G.P./Alliance Global Partners (NYSE:GLP) is acting as the sole placement agent for the offering. Cibus continues to advance its gene-editing platforms, with plans for a 2027 commercial launch for certain products. Despite these developments, the company’s stock has experienced a downturn, attributed to the offering’s steep discount to the market price.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.